Chemotherapy and antiangiogenesis: Drug-specific, dose-related effects

Acta Oncologica

Volumn 42, Issue 4, 2003, Pages 294-303

  Lennernäs, Bo ^a   Albertsson, Per ^a   Lennernäs, Hans ^b   Norrby, Klas ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DRUG DOSAGE; DRUG INTERACTIONS; GENETIC ENGINEERING; TUMORS;

ANGIOGENESIS;

ONCOLOGY;

ANGIOGENESIS INHIBITOR; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOFOS; ETOPOSIDE; FAULDING; FLUOROURACIL; METHOTREXATE; PACLITAXEL; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; BODY WEIGHT; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENDOTHELIAL GROWTH FACTORS; ETOPOSIDE; FLUOROURACIL; HUMANS; INJECTIONS, INTRAVENOUS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MALE; MESENTERY; METHOTREXATE; NEOVASCULARIZATION, PHYSIOLOGIC; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; WEIGHT GAIN;

EID: 0038502269     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310001835     Document Type: Article

References (36)

1. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-86.
2. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15-24.
3. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105: 1045-7.
4. Miller KD, Sweeney CJ, Sledge Jr GW. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001; 19: 1195-206.
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
6. Stein I, Keshet E. Regulation of vascular endothelial growth factor (VEGF) expression. In: Voest EE, D'Amore PA, eds. Tumor angiogenesis and microcirculation. New York: Marcel Dekker, 2001: 213-26.
7. Ferrara N. Role of vascular endothelial growth factor in angiogenesis. In: Rubanyi GM, ed. Angiogenesis in health and disease. New York: Marcel Dekker, 2001: 47-73.
8. Workman P, Twentyman P, Balkwill F, et al. United Kingdom co-ordinating committee on cancer research (UKCCCR) guidelines for welfare of animals in experimental neoplasia. 2nd ed. Br J Cancer 1998; 77: 1-10.
9. Norrby K. Vascular endothelial growth factor and de novo mammalian angiogenesis. Microvasc Res 1996; 51: 154-63.
10. Mukhopadhyay D, Nagy JA, Manseau EJ, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. Cancer Res 1998; 58: 1278-84.
11. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966; 50: 219-44.
12. Norrby K. Basic fibroblast growth factor and de novo mammalian angiogenesis. Microvasc Res 1994; 48: 96-113.
13. Norrby K, Mattsby-Baltzer I, Innocenti M, Tuneberg S. Orally administered bovine lactoferrin systemically inhibits VEGF165-mediated angiogenesis in the rat. Int J Cancer 2001; 91: 236-40.
14. Norrby K. Microvascular density in terms of number and length of microvessel segments per unit tissue volume in mammalian angiogenesis. Microvasc Res 1998; 55: 43-53.
15. Näslund I, Norrby K. NO and de novo angiogenesis: Further evidence that NO inhibits bFGF-induced angiogenesis while not influencing VEGF165-induced angiogenesis. APMIS 2000; 108: 29-37.
16. Poiley SM. Growth tables for 66 strains and stocks of laboratory animals. Lab Animal Sci 1972; 22: 759-79.
17. Norrby K. 2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165-mediated mammalian angiogenesis. Int J Exp Path 2000; 81: 191-8.
18. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogen 2000; 21: 505-15.
19. Schirner M. Antiangiogenic chemotherapeutic agents. Cancer Metastasis Rev 2000; 19: 67-73.
20. StCroix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000; 289: 1197-202.
21. Klement G, Huang P, Mayer B, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multi-resistant human breast cancer xenografts. Clin Cancer Res 2002; 8: 221-32.
22. Kerbel RS, Viloria-Petit A, Klement G, Rak J. 'Accidental' anti-angiogenic drugs, anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000; 36: 1248-57.
23. Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001; 86: 23-33.
24. Fidler IJ, Ellis LM. Chemotherapeutic drugs - more really is not better. Natl Med 2000; 6: 500-2.
25. Ruoslahti E, Rajotte D. An address in the vasculature of normal tissues and tumors. Ann Rev Immunol 2000; 18: 813-27.
26. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000; 156: 361-81.
27. Venkateswar RJ, Lam SS, Boudinot FD. Nonlinear harmacokinetics of 5-fluorouracil in rats. J Pharm Sci 1997; 86: 756-8.
28. Coudore F, Authier N, Guillaume D, Beal D, Duroux E, Fialip J. High-performance liquid chromatographic determination of paclitaxel in rat serum: application to a toxicokinetic study. J Chromatogr B Biomed Sci Appl 1999; 721: 317-20.
29. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 1999; 16: 1564-9.
30. Takada K, Kawamura T, Inai M, et al. Pharmacokinetics of cisplatin in analbuminemic rats. Biopharm Drug Dispos 1999; 20: 421-8.
31. Hanada K, Ninoiya K, Ogata H. Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin. J Pharm Pharmacol 2000; 52: 1345-53.
32. Kim MM, Lee SH, Lee MG, Hwang SJ, Kim CK. Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. Biopharm Drug Dispos 1995; 16: 279-93.
33. Yu LJ, Drewes P, Gustavsson K, Brain EG, Hecht JE, Waxman DJ. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumour activity. J Pharmacol Exp Ther 1999; 288: 928-37.
34. Burgio DE, Gosland MP, McNamara PJ. Effects of P-glycoprotein modulators of etoposide elimination and central nervous system distribution. J Pharmacol Exp Ther 1998; 287: 911-7.
35. Rocca A, Colleoni M, Nole F, et al. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer. Antitumor activity and correlations with serum vascular endothelium growth factor. Proc Am Soc Clin Oncol 1999; 18: 121a.
36. Marchetti P, Urien S, Cappellini GA, Ronzino G, Ficorella C. Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hematol (Suppl) 2002; 44: S3-13.